<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Urol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Urol</journal-id><journal-id journal-id-type="pmc-domain-id">67</journal-id><journal-id journal-id-type="pmc-domain">bmcurol</journal-id><journal-title-group><journal-title>BMC Urology</journal-title></journal-title-group><issn pub-type="epub">1471-2490</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12067709</article-id><article-id pub-id-type="pmcid-ver">PMC12067709.1</article-id><article-id pub-id-type="pmcaid">12067709</article-id><article-id pub-id-type="pmcaiid">12067709</article-id><article-id pub-id-type="pmid">40355842</article-id><article-id pub-id-type="doi">10.1186/s12894-025-01792-w</article-id><article-id pub-id-type="publisher-id">1792</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohort</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Fraslin</surname><given-names initials="A">Ald&#233;ric</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Colrat</surname><given-names initials="F">Florian</given-names></name><address><email>florian.colrat@bms.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karimi</surname><given-names initials="M">Maryam</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bonastre</surname><given-names initials="J">Julia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Groussard</surname><given-names initials="K">Karine</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teitsson</surname><given-names initials="S">Siguroli</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prudent</surname><given-names initials="A">Alexis</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Branchoux</surname><given-names initials="S">S&#233;bastien</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Radvanyi</surname><given-names initials="F">Fran&#231;ois</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Benhamou</surname><given-names initials="S">Simone</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Allory</surname><given-names initials="Y">Yves</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lebret</surname><given-names initials="T">Thierry</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xjwb503</institution-id><institution-id institution-id-type="GRID">grid.460789.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 4910 6535</institution-id><institution>Bureau Biostatistique et Epid&#233;miologie, </institution><institution>Gustave Roussy, Universit&#233; Paris-Saclay, </institution></institution-wrap>Villejuif, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vjkv261</institution-id><institution-id institution-id-type="GRID">grid.7429.8</institution-id><institution-id institution-id-type="ISNI">0000000121866389</institution-id><institution>INSERM, Universit&#233; Paris-Saclay, CESP U1018 Oncostat, Labelis&#233; Ligue Contre le Cancer, </institution></institution-wrap>Villejuif, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013b57229</institution-id><institution-id institution-id-type="GRID">grid.481843.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1795 0897</institution-id><institution>Health Economics and Outcomes Research, Bristol Myers Squibb, </institution></institution-wrap>Rueil-Malmaison, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vjkv261</institution-id><institution-id institution-id-type="GRID">grid.7429.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2186 6389</institution-id><institution>INSERM, </institution></institution-wrap>Paris, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047933096</institution-id><institution-id institution-id-type="GRID">grid.512413.0</institution-id><institution>Health Economics and Outcomes Research, </institution><institution>Bristol Myers Squibb Pharmaceuticals Ltd, </institution></institution-wrap>Uxbridge, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013b57229</institution-id><institution-id institution-id-type="GRID">grid.481843.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1795 0897</institution-id><institution>Medical Affairs Department, </institution><institution>Bristol Myers Squibb, </institution></institution-wrap>Rueil-Malmaison, France </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04t0gwh46</institution-id><institution-id institution-id-type="GRID">grid.418596.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 6384</institution-id><institution>UMR 144 CNRS, Institut Curie, </institution></institution-wrap>Paris, France </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/058td2q88</institution-id><institution-id institution-id-type="GRID">grid.414106.6</institution-id><institution-id institution-id-type="ISNI">0000 0000 8642 9959</institution-id><institution>Department of Urology, </institution><institution>H&#244;pital Foch, </institution></institution-wrap>Suresnes, France </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478196</issue-id><elocation-id>120</elocation-id><history><date date-type="received"><day>12</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>12</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-15 08:25:40.150"><day>15</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12894_2025_Article_1792.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To describe characteristics, management, disease-free survival and overall survival of patients with muscle-invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR) undergoing radical cystectomy in France and a subgroup of these patients who did not receive adjuvant chemotherapy after RC and were managed with active surveillance only (MIBC-HR-ASO).</p></sec><sec><title>Methods</title><p id="Par2">Patients aged&#8201;&#8805;&#8201;18 years with MIBC who had radical cystectomy from October 2012 to June 2018 were identified in the prospective COBLAnCE bladder cancer cohort. Patients with metastatic disease were excluded. Patients were classified as MIBC-HR based on TNM staging. Disease-free and overall survival were estimated using the Kaplan-Meier method with their 95% confidence intervals (95%CI).</p></sec><sec><title>Results</title><p id="Par3">256 patients with MIBC-HR were enrolled. The median age at diagnosis was 68.5 years and 204 patients were men (79.7%). 201 patients (78.5%) were current or former smokers. For staging, 226 patients were (y)pT3a or higher (88.3%) and 132 were N- (51.6%). Forty-six patients received neoadjuvant chemotherapy (18.0%), and 69 received adjuvant chemotherapy (27.0%). Of the patients receiving adjuvant chemotherapy only, 59 received cisplatin-based therapy (86.8%). 182 patients (71.1%) constituted the ASO subgroup. 175 patients (68.3%) experienced an event up to the end of follow-up. Median follow-up was 5.0 years. Median disease-free survival was 1.30 years [95%CI: 1.01&#8211;1.60] in the MIBC-HR cohort and 1.21 years [95%CI: 0.70&#8211;1.53] in the MIBC-HR-ASO subgroup. Median overall survival was 2.31 years [95%CI: 1.85&#8211;3.10] in the MIBC-HR cohort and 2.11 years [95%CI: 1.61&#8211;2.65] in the MIBC-HR-ASO subgroup. At 5 years, DFS was 27.4% [21.7;33.9%] in the MIBC-HR population and 23.7% [17.4;31.4] in the MIBC-HR-ASO population. OS at five years was 33.2% [27.1;40.0] for the MIBC-HR population and 29.6% [22.7;37.7] for the MIBC-HR-ASO population.</p></sec><sec><title>Conclusion</title><p id="Par4">Using real-world data, this study underscores the challenging prognosis of patients with MIBC-HR managed with RC, regardless of whether they receive adjuvant chemotherapy. New treatment protocols, such as the use of immunotherapies, may improve OS in this type of cancer, especially in the current therapeutic landscape where no highly effective treatment exists.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12894-025-01792-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bladder cancer</kwd><kwd>Muscle-invasive urothelial carcinoma</kwd><kwd>Radical cystectomy</kwd><kwd>Adjuvant chemotherapy</kwd><kwd>Survival</kwd><kwd>Prospective cohort</kwd></kwd-group><funding-group><award-group><funding-source><institution>French Ministry of Research (Programme Investissements d&#8217;Avenir Cohortes)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>National League against Cancer</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Institute of Research in Public Health - National Institute of Health and Medical Research</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Bristol Myers Squibb</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Bladder cancer (BC) accounts for 3% of cancer diagnoses worldwide, with 573,000 people having been diagnosed with BC in 2018 [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">In BC, the tumour is initially restricted to the epithelial or sub-epithelial connective tissue layer, and around 70% of cases are diagnosed and treated at this stage (non-muscle-invasive BC) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. As the tumour develops, it may infiltrate the muscle tissue layer of the bladder wall. Muscle-invasive BC (MIBC), has a poorer prognosis and carries a high risk of recurrence, either locally or through metastatic spread and, for this reason, requires more aggressive treatment [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par7">The gold standard treatment for MIBC is radical cystectomy (RC). The European Association of Urology (EAU) guidelines, published in 2020 and updated in 2023, recommend neoadjuvant chemotherapy with cisplatin for all eligible patients [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. These guidelines also strongly advocate the use of adjuvant chemotherapy in patients with &#8216;high-risk of recurrence&#8217; who did not receive neoadjuvant treatment, despite the absence of a consensus definition for &#8216;high risk of recurrence&#8217; [<xref ref-type="bibr" rid="CR5">5</xref>]. In France, current use of neoadjuvant and adjuvant chemotherapy is poorly characterised and has been disputed [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par8">COBLAnCE is a multicentre (14 centres), observational prospective cohort of newly diagnosed patients with BC initiated in 2012, designed to investigate the impact of environmental and genetic factors on prognosis and to generate real-world data on treatment patterns in BC in the French setting [<xref ref-type="bibr" rid="CR9">9</xref>]. By 2018, 1,800 patients had been enrolled and prospectively followed over a 6-year period, making it the largest prospective cohort in this disease in Europe. The COBLAnCE cohort represents an extremely rich source of real-world data which are increasingly required by health authorities to assess innovative treatments. Here, we report results for a subgroup of the cohort, focusing on patients with MIBC at high risk of recurrence (MIBC-HR) who had undergone RC. Our study describes patient characteristics, treatment, disease-free survival (DFS) and overall survival (OS) in MIBC-HR patients and a subgroup of these patients who did not receive adjuvant chemotherapy after RC and were managed with active surveillance only (MIBC-HR-ASO).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par9">This study was performed using the prospective COBLAnCE cohort, which has been described in detail elsewhere [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Patients were included in the COBLAnCE cohort from October 2012 until June 2018, with a 6-year planned follow-up. The COBLAnCE cohort included patients with newly diagnosed BC and aged 18 years or older. For the current study, only patients with MIBC-HR who had undergone RC were selected. High-risk of recurrence was defined by pathological stage of pT3-pT4a, ypT2-ypT4a, or (y)pN&#8201;+&#8201;according to the TNM classification [<xref ref-type="bibr" rid="CR5">5</xref>]. Patients with metastatic disease at radical resection were excluded, as were patients receiving an experimental immunotherapy treatment in the adjuvant setting. A subgroup of patients not receiving adjuvant chemotherapy and followed with active surveillance only (MIBC-HR-ASO) was also evaluated.</p></sec><sec id="Sec4"><title>Patient characteristics</title><p id="Par10">The COBLAnCE data collection has been detailed previously [<xref ref-type="bibr" rid="CR10">10</xref>]. We considered sociodemographic and lifestyle characteristics at inclusion, such as age, gender, body mass index (calculated from height and weight) and smoking status (Never/Former/Current). Comorbidities such as hypertension, diabetes, heart failure, and angina pectoris were assessed by interview at enrolment and renal function was described by serum creatinine (&#181;mol/L) and glomerular filtration rate (mL/min/1.72 m<sup>2</sup>) reported in the medical records at inclusion, as described previously [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par11">We also documented tumour characteristics at the time of surgery, such as tumour stage (pT0/pT1/pT2/pT3a/pT3b/pT4a), nodal status (N+/N-/Nx) and histological type of initial tumour (urothelial carcinoma/other) and the histological variant (conventional/micropapillary/multiple variants/squamous/other).</p></sec><sec id="Sec5"><title>Survival outcomes</title><p id="Par12">During the follow-up period, we considered any observed disease recurrence or any death as an event. Recurrence was defined as either loco-regional or distant. The considered endpoints were OS, defined as the time between RC and death from any cause and DFS, defined as the time between RC and the first disease recurrence or death from any cause, whichever occurred first. All patients were followed for a maximum of six years and the administrative censoring date was set at 24<sup>th</sup> January 2022. Patients for whom no events had been observed were censored at their last follow-up visit or at the end of follow-up (administrative censoring due to the 6-year maximum follow-up).</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par13">Data presentation is purely descriptive and no statistical hypotheses were tested. Descriptive statistics are presented with mean values and standard deviations (SD) for continuous variables and as frequency counts and percentages for categorical variables, with a separate category for missing data. Median follow-up time was assessed using the reverse KaplanMeier method. Survival outcomes were evaluated using the Kaplan-Meier method, and median survival durations were determined with their 95% confidence intervals (95% CI). OS was described as median and 5-year OS, while DFS was described as median, 2-year and 5-year DFS. Statistical analyses were performed using SAS<sup>&#174;</sup> software Version 9.4 (SAS Institute Inc. Cary, NC, USA).</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Study population</title><p id="Par14">The COBLAnCE cohort enrolled 1,800 patients with BC aged&#8201;&#8805;&#8201;18 years between 2012 and 2018. Of these, 431 non-metastatic patients with MIBC undergoing RC were identified, of whom 256 were at high risk of recurrence. These 256 patients constituted the study population. Of these patients, 182 (71.0%) received no adjuvant chemotherapy (ASO subgroup). A flowchart illustrating the selection of patients is provided in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par15">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Patient flow and use of chemotherapy in patients with muscle invasive urothelial carcinoma</p><p>*one patient received adjuvant radiotherapy</p><p>ASO: active surveillance alone; BC: bladder cancer, MIBC: muscle invasive bladder cancer, RC: radical cystectomy</p><p>The percentages are calculated with respect to the number in the box above</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e406" position="float" orientation="portrait" xlink:href="12894_2025_1792_Fig1_HTML.jpg"/></fig>
</p><p id="Par16">Patient characteristics are presented in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. MIBC-HR patients were principally men (79.7%), with a mean age of 68.5&#8201;&#177;&#8201;10.6 years and the majority were current (28.8%, <italic toggle="yes">n</italic>&#8201;=&#8201;72) or formersmokers (51.6%, <italic toggle="yes">n</italic>&#8201;=&#8201;129). Most patients (78.3%) had impaired renal function (glomerular filtration rate&#8201;&#8804;&#8201;90&#160;ml/min) and 42.5% had a history of hypertension. No major differences were observed between the MIBC-HR and the MIBC-HR-ASO patients, although the latter group was older and certain comorbidities were slightly more frequent.</p><p id="Par17">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patient and tumour characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">MIBC-HR<break/>(all patients)<break/><italic toggle="yes">N</italic>&#8201;=&#8201;256</th><th align="left" colspan="1" rowspan="1">MIBC-HR <break/>(ASO)<break/><italic toggle="yes">N</italic>&#8201;=&#8201;182</th><th align="left" colspan="1" rowspan="1">MIBC-HR<break/>(Adj. Chemo.)<break/><italic toggle="yes">N</italic>&#8201;=&#8201;74</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender (n; %)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td align="left" colspan="1" rowspan="1">204 (79.7%)</td><td align="left" colspan="1" rowspan="1">148 (81.3%)</td><td align="left" colspan="1" rowspan="1">56 (75.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="left" colspan="1" rowspan="1">52 (20.3%)</td><td align="left" colspan="1" rowspan="1">34 (18.7%)</td><td align="left" colspan="1" rowspan="1">18 (24.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Age at diagnosis (years; mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">68.5&#8201;&#177;&#8201;10.6</td><td align="left" colspan="1" rowspan="1">70.2&#8201;&#177;&#8201;10.7</td><td align="left" colspan="1" rowspan="1">64.2&#8201;&#177;&#8201;8.9</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&lt;&#8201;50</td><td align="left" colspan="1" rowspan="1">15 (5.9%)</td><td align="left" colspan="1" rowspan="1">11 (6.0%)</td><td align="left" colspan="1" rowspan="1">4 (5.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;51&#8211;60</td><td align="left" colspan="1" rowspan="1">44 (17.2%)</td><td align="left" colspan="1" rowspan="1">24 (13.1%)</td><td align="left" colspan="1" rowspan="1">20 (27.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;61&#8211;70</td><td align="left" colspan="1" rowspan="1">88 (34.4%)</td><td align="left" colspan="1" rowspan="1">55 (30.2%)</td><td align="left" colspan="1" rowspan="1">33 (44.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;71&#8211;80</td><td align="left" colspan="1" rowspan="1">71 (27.7%)</td><td align="left" colspan="1" rowspan="1">57 (31.3%)</td><td align="left" colspan="1" rowspan="1">14 (19.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&gt;&#8201;80</td><td align="left" colspan="1" rowspan="1">38 (14.8%)</td><td align="left" colspan="1" rowspan="1">35 (29.2%)</td><td align="left" colspan="1" rowspan="1">3 (4.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI at inclusion (kg/m&#178;; mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">25.9&#8201;&#177;&#8201;4.9</td><td align="left" colspan="1" rowspan="1">26.0&#8201;&#177;&#8201;5.2</td><td align="left" colspan="1" rowspan="1">25.5&#8201;&#177;&#8201;4.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking status at inclusion</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;250</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;176</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;74</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Never smoked</td><td align="left" colspan="1" rowspan="1">49 (19.6%)</td><td align="left" colspan="1" rowspan="1">31 (17.6%)</td><td align="left" colspan="1" rowspan="1">18 (24.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Former smoker</td><td align="left" colspan="1" rowspan="1">129 (51.6%)</td><td align="left" colspan="1" rowspan="1">93 (52.8%)</td><td align="left" colspan="1" rowspan="1">36 (48.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Current smoker</td><td align="left" colspan="1" rowspan="1">72 (28.8%)</td><td align="left" colspan="1" rowspan="1">52 (29.5%)</td><td align="left" colspan="1" rowspan="1">20 (27.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum creatinine (&#181;mol/L; mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">110&#8201;&#177;&#8201;48</td><td align="left" colspan="1" rowspan="1">112&#8201;&#177;&#8201;50</td><td align="left" colspan="1" rowspan="1">106&#8201;&#177;&#8201;45</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">62</td><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">46</td></tr><tr><td align="left" colspan="1" rowspan="1">Estimated glomerular filtration rate (mL/min/1.72&#160;m&#178;)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;189</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;131</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;58</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">11 (5.8%)</td><td align="left" colspan="1" rowspan="1">9 (6.9%)</td><td align="left" colspan="1" rowspan="1">2 (3.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;30&#8211;59</td><td align="left" colspan="1" rowspan="1">68 (36.0%)</td><td align="left" colspan="1" rowspan="1">50 (38.1%)</td><td align="left" colspan="1" rowspan="1">18 (31.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;60&#8211;89</td><td align="left" colspan="1" rowspan="1">69 (36.5%)</td><td align="left" colspan="1" rowspan="1">44 (33.6%)</td><td align="left" colspan="1" rowspan="1">25 (43.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&gt;&#8201;90</td><td align="left" colspan="1" rowspan="1">41 (21.7%)</td><td align="left" colspan="1" rowspan="1">28 (21.4%)</td><td align="left" colspan="1" rowspan="1">13 (22.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">67</td><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">16</td></tr><tr><td align="left" colspan="1" rowspan="1">Comorbidities</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1">105 (42.5%)</td><td align="left" colspan="1" rowspan="1">73 (41.7%)</td><td align="left" colspan="1" rowspan="1">32 (44.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes</td><td align="left" colspan="1" rowspan="1">39 (15.9%)</td><td align="left" colspan="1" rowspan="1">31 (17.8%)</td><td align="left" colspan="1" rowspan="1">8 (11.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Heart failure</td><td align="left" colspan="1" rowspan="1">23 (9.3%)</td><td align="left" colspan="1" rowspan="1">18 (10.3%)</td><td align="left" colspan="1" rowspan="1">5 (6.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Angina pectoris</td><td align="left" colspan="1" rowspan="1">28 (11.4%)</td><td align="left" colspan="1" rowspan="1">23 (13.2%)</td><td align="left" colspan="1" rowspan="1">5 (6.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Histological type of initial tumour</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urothelial carcinoma</td><td align="left" colspan="1" rowspan="1">239 (94.5%)</td><td align="left" colspan="1" rowspan="1">168 (93.9%)</td><td align="left" colspan="1" rowspan="1">71 (95.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other</td><td align="left" colspan="1" rowspan="1">14 (5.5%)</td><td align="left" colspan="1" rowspan="1">11 (6.1%)</td><td align="left" colspan="1" rowspan="1">3 (4.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Adenocarcinoma (primary urinary bladder or urachal)</td><td align="left" colspan="1" rowspan="1">3 (1.2%)</td><td align="left" colspan="1" rowspan="1">2 (1.1%)</td><td align="left" colspan="1" rowspan="1">1 (1.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neuroendocrine carcinoma (admixed with urothelial carcinoma)</td><td align="left" colspan="1" rowspan="1">5 (2.0%)</td><td align="left" colspan="1" rowspan="1">4 (2.2%)</td><td align="left" colspan="1" rowspan="1">1 (1.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neuroendocrine carcinoma (pure)</td><td align="left" colspan="1" rowspan="1">1 (0.4%)</td><td align="left" colspan="1" rowspan="1">1 (0.6%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Squamous carcinoma (pure)</td><td align="left" colspan="1" rowspan="1">5 (2.0%)</td><td align="left" colspan="1" rowspan="1">4 (2.2%)</td><td align="left" colspan="1" rowspan="1">1 (1.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Histological variant (urothelial carcinoma or admixed with urothelial carcinoma)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Conventional</td><td align="left" colspan="1" rowspan="1">124 (50.8%)</td><td align="left" colspan="1" rowspan="1">93 (54.1%)</td><td align="left" colspan="1" rowspan="1">31 (43.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Micropapillary</td><td align="left" colspan="1" rowspan="1">17 (7.0%)</td><td align="left" colspan="1" rowspan="1">12 (7.0%)</td><td align="left" colspan="1" rowspan="1">5 (6.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Multiple variants</td><td align="left" colspan="1" rowspan="1">25 (10.2%)</td><td align="left" colspan="1" rowspan="1">13 (7.6%)</td><td align="left" colspan="1" rowspan="1">12 (16.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Squamous</td><td align="left" colspan="1" rowspan="1">46 (18.9%)</td><td align="left" colspan="1" rowspan="1">33 (19.2%)</td><td align="left" colspan="1" rowspan="1">13 (18.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other</td><td align="left" colspan="1" rowspan="1">32 (13.1%)</td><td align="left" colspan="1" rowspan="1">21 (12.2%)</td><td align="left" colspan="1" rowspan="1">11 (15.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumour stage at radical resection</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;pT0</td><td align="left" colspan="1" rowspan="1">1 (0.4%)</td><td align="left" colspan="1" rowspan="1">1 (0.5%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;pT1</td><td align="left" colspan="1" rowspan="1">3 (1.2%)</td><td align="left" colspan="1" rowspan="1">3 (1.6%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;pT2</td><td align="left" colspan="1" rowspan="1">26 (10.2%)</td><td align="left" colspan="1" rowspan="1">20 (11.0%)</td><td align="left" colspan="1" rowspan="1">6 (8.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;pT3a</td><td align="left" colspan="1" rowspan="1">78 (30.5%)</td><td align="left" colspan="1" rowspan="1">58 (31.9%)</td><td align="left" colspan="1" rowspan="1">20 (27.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;pT3b</td><td align="left" colspan="1" rowspan="1">88 (34.4%)</td><td align="left" colspan="1" rowspan="1">59 (32.4%)</td><td align="left" colspan="1" rowspan="1">29 (39.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;pT4a</td><td align="left" colspan="1" rowspan="1">60 (23.4%)</td><td align="left" colspan="1" rowspan="1">41 (22.5%)</td><td align="left" colspan="1" rowspan="1">19 (25.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nodal status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;N+</td><td align="left" colspan="1" rowspan="1">97 (37.9%)</td><td align="left" colspan="1" rowspan="1">53 (29.1%)</td><td align="left" colspan="1" rowspan="1">44 (59.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;N-</td><td align="left" colspan="1" rowspan="1">132 (51.6%)</td><td align="left" colspan="1" rowspan="1">105 (57.7%)</td><td align="left" colspan="1" rowspan="1">27 (36.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Nx</td><td align="left" colspan="1" rowspan="1">27 (10.5%)</td><td align="left" colspan="1" rowspan="1">24 (13.2%)</td><td align="left" colspan="1" rowspan="1">3 (4.1%)</td></tr></tbody></table><table-wrap-foot><p>ASO: active surveillance only; MIBC-HR: muscle invasive bladder cancer at high risk of recurrence; SD: standard deviation; Adj. Chemo.: adjuvant chemotherapy</p></table-wrap-foot></table-wrap>
</p><p id="Par18">Almost all RC interventions were performed by laparotomy (96.5%). Of the 204 men, 202 underwent total cystoprostatectomy (99.0%) and 46 of the 52 women (88.5%) underwent front pelvectomy. Lymph node dissection was performed in 89.8% of the patients. More information on surgical techniques is provided in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par19">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Description of radical cystectomy interventions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">MIBC-HR<break/><italic toggle="yes">N</italic>&#8201;=&#8201;256</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Surgical access</bold>
</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;228</td></tr><tr><td align="left" colspan="1" rowspan="1">Laparotomy</td><td align="left" colspan="1" rowspan="1">220 (96.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Coelioscopy</td><td align="left" colspan="1" rowspan="1">6 (2.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Robot</td><td align="left" colspan="1" rowspan="1">2 (0.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Type of surgery in radical cystectomy</bold>
</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;256</td></tr><tr><td align="left" colspan="1" rowspan="1">Cystectomy with conservation of pelvic system (women)</td><td align="left" colspan="1" rowspan="1">6 (2.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cystectomy without prostatectomy (men)</td><td align="left" colspan="1" rowspan="1">2 (0.8%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Front pelvectomy (women)</td><td align="left" colspan="1" rowspan="1">46 (18.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Total cystoprostatectomy (men)</td><td align="left" colspan="1" rowspan="1">202 (78.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>
<bold>Lymph node dissection</bold>
</p><p>No</p><p>Yes</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">N</italic>&#8201;=&#8201;256</p><p>26 (10.2%)</p><p>230 (89.8%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>
<bold>Type of dissection</bold>
</p><p>No dissection</p><p>Local</p><p>Extended</p><p>Supraextended</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">N</italic>&#8201;=&#8201;245</p><p>26 (10.6%)</p><p>124 (50.6%)</p><p>92 (37.6%)</p><p>3 (1.2%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>
<bold>Urinary bypass</bold>
</p><p>Bricker</p><p>Orthotopic Neobladder</p><p>Skin continent bypass</p><p>Ureterostomy</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">N</italic>&#8201;=&#8201;254</p><p>157 (61.8%)</p><p>72 (28.3%)</p><p>3 (1.2%)</p><p>22 (8.7%)</p></td></tr></tbody></table></table-wrap>
</p><p id="Par20">Tumour characteristics at the time of RC are presented in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The principal tumour type was urothelial carcinoma, accounting for more than 90% of cases, and the histological variant was conventional for more than half of the patients. Regarding tumour staging, the majority were pT3a+ (88.3%), and 37.9% had nodal involvement. The tumour characteristics of MIBC-HR-ASO patients were similar to those of MIBC-HR patients, except for the proportion with nodal involvement, which was lower than nodal involvement in MIBC-HR patients (29.1% vs. 37.9%).</p></sec><sec id="Sec9"><title>Chemotherapy</title><p id="Par21">The use of neoadjuvant and adjuvant chemotherapy is described in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. Overall, over half of the 256 patients did not receive either neoadjuvant or adjuvant chemotherapy (<italic toggle="yes">n</italic>&#8201;=&#8201;140; 54.7%), 41 patients (16.0%) received neoadjuvant chemotherapy only, and 69 patients (27.0%) received adjuvant chemotherapy only. MIBC-HR-ASO patients accounted for 71.1% of MIBC-HR patients (<italic toggle="yes">n</italic>&#8201;=&#8201;186). Of the patients receiving adjuvant chemotherapy only, 86.8% received cisplatin-based therapy (<italic toggle="yes">n</italic>&#8201;=&#8201;59). The other adjuvant chemotherapies were carboplatin-based protocols (4 patients, 10.0%) or other unspecified therapies (5 patients, 12.5%).</p></sec><sec id="Sec10"><title>Survival outcomes</title><p id="Par22">The median follow-up was 5.0 years. Median OS was 2.31 years [95% CI: 1.85;3.10] in the MIBC-HR population and 2.11 years [95% CI: 1.61;2.65] in the MIBC-HR-ASO population (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A, C). At 5 years, OS was 33.2% [27.1;40.0] and 29.6% [22.7;37.7] in the MIBC-HR and in the MIBC-HR-ASO populations. Median DFS was 1.30 years [95% CI: 1.01;1.60] in the MIBC-HR population and 1.21 years [95% CI: 0.70;1.53] in the subgroup of MIBC-HR-ASO population (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B, D). At 2 and 5 years respectively, DFS was 39.9% [33.9;46.2] and 27.4% [21.7;33.9%] in the MIBC-HR population and was 37.9% [31.0;45.4] and 23.7% [17.4;31.4] in the MIBC-HR-ASO population.</p><p id="Par23">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Overall survival and disease-free survival of patients with muscle invasive urothelial carcinoma (overall and restricted to those treated with active surveillance only). <bold>A</bold>: overall survival, MIBC-HR patients; <bold>B</bold>: disease-free survival, MIBC-HR patients; <bold>C</bold>: overall survival, MIBC-HR-ASO patients; <bold>D</bold>: disease-free survival, MIBC-HR-ASO patients</p><p>95% CI: 95% confidence interval; DFS: disease-free survival; MIBC-HR: muscle-invasive bladder cancer at high risk of recurrence; MIBC-HR-ASO: muscle-invasive bladder cancer at high risk of recurrence treated with active surveillance only; OS: overall survival</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1189" position="float" orientation="portrait" xlink:href="12894_2025_1792_Fig2_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par24">This study focused on 256 patients with MIBC-HR undergoing RC who participated in the COBLAnCE cohort. The majority were aged&#8201;&gt;&#8201;70 years, had a history of smoking and presented with a histology of urothelial carcinoma. Their prognosis was poor, with 61.7% of included patients dying within six years of undergoing RC (median survival duration: 2.31 years). These characteristics are typical of patients with BC [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par25">Current EAU guidelines recommend offering neoadjuvant cisplatin-based combination therapy for patients with T2-T4a cN0M0 BC and adjuvant cisplatin-based combination chemotherapy to patients with pT3/4 or pN&#8201;+&#8201;disease, if no neoadjuvant chemotherapy had been given previously [<xref ref-type="bibr" rid="CR7">7</xref>]. Based on real-world data from the COBLAnCE cohort, adherence to these recommendations in France appears to be poor, since only 18% of patients received neoadjuvant chemotherapy, and only up to 30% (69/209) of patients received adjuvant chemotherapy without neoadjuvant chemotherapy. Our study suggests that the decision to provide adjuvant chemotherapy did not seem to have been influenced by the tumour stage. However, for the patients who did receive adjuvant chemotherapy, 86.8% received a cisplatin-based treatment as recommended in the guidelines, and the recommended number of cycles were administered in most cases (see Supplementary &#8211; Table <xref rid="MOESM1" ref-type="media">A</xref>). The prescription of the sequence neoadjuvant chemotherapy followed by adjuvant chemotherapy was very low, as per guidelines.</p><p id="Par26">In terms of survival outcomes, comparison of DFS or OS for patients with MIBC-HR or MIBC-HR-ASO with findings from other studies is limited by the scarcity of available data and the lack of a common consensus definition of &#8220;high risk&#8221; of recurrence. Although our study did not show worse survival rates for the subgroup of patients not receiving adjuvant chemotherapy, it is important to note that the study was not designed to detect such a difference. In particular, patients from this subgroup were older and might not have been fit for adjuvant chemotherapy. Other features, including glomerular filtration rates and comorbidities did not differ susbstantially. In the literature, evidence for the benefit of adjuvant chemotherapy in MIBC is not particularly robust and is at high risk of bias [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. A large randomised clinical trial (EORTC 30994) comparing immediate adjuvant chemotherapy after RC to delayed chemotherapy at the time of recurrence in 284 patients with MIBC failed to show a significant improvement in OS in patients receiving adjuvant chemotherapy [<xref ref-type="bibr" rid="CR13">13</xref>]. In this clinical trial, the median OS was significantly higher than in our study (median OS: 6.74 years vs. 27.7 months), probably due to the enrolment of a significant number of patients aged over 80 years (14.8%) in the COBLAnCE cohort. On the other hand, two large studies using the US National Cancer Database found that the benefit is restricted to certain histological tumour types [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par27">This study has important strengths, notably its use of the only prospective BC cohort in France that documents detailed clinical characteristics for patients, with a follow-up duration of up to six years. The use of an established cohort has many advantages, notably the wealth of clinical information available on participants documented in a standardised way. However, the study also presents limitations: for example, only 14 hospitals enrolled patients, which limited the number of patients who could be enrolled and may have led to selection bias. Alternative study designs, such as extracting data on patients with MIBC from health insurance databases, would allow recruitment of a larger and more exhaustive population but can only provide limited clinical information. A study of MIBC based on the French national hospital database (<italic toggle="yes">Programme de M&#233;dicalisation des Syst&#232;mes d&#8217;Information</italic>; PMSI), which enrolled more than 2,500 patients with MIBC who had undergone RC in 2015, provided similar findings on demographics and overall survival to the present study [<xref ref-type="bibr" rid="CR16">16</xref>]. However, it was not possible to stratify patients by risk of recurrence in this PMSI study due to the absence of relevant clinical data in the PMSI database [<xref ref-type="bibr" rid="CR16">16</xref>]. Another limitation of the present study is that patients with a history of treatment for non-muscle invasive BC were not enrolled. According to a recent meta-analysis, such patients could have a worse prognosis than those without such a history (hazard ratio for cancer-specific survival: 1.29, 95% CI: [1.07&#8211;1.56]) [<xref ref-type="bibr" rid="CR17">17</xref>]. A final limitation relates to the period of inclusion in the COBLAnCE cohort. Between 2012 and 2018, immunotherapies for BC were still under development, and for this reason, patients receiving immunotherapies in the context of a clinical trial were excluded from the study population. Treatments shown to improve survival recently became available after the end of the enrolment period of the COBLAnCE cohort [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], which may thus not be fully representative of the current French therapeutic landscape. Nonetheless, the COBLAnCE cohort remains a highly valuable source for documenting the current landscape of patients with MIBC and MIBC-HR in France.</p></sec><sec id="Sec12"><title>Conclusions</title><p id="Par28">Using real-world data, this study underscores the challenging prognosis of patients with MIBC-HR managed with RC, regardless of whether they receive adjuvant chemotherapy. New treatment protocols, such as the use of immunotherapies, may improve OS in this type of cancer, especially in the current therapeutic landscape where no highly effective treatment exists.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12894_2025_1792_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Writing and editorial assistance was provided by SARL Foxymed.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published. AF, FC, JB, KG, ST, AP, SBr, SBe, YA and TL designed the study. MK, JB, KG SBe and TL acquired the data. AF, FC, MK, JB, SBr, FR, YA and TL analysed the data. AF, FC, JB, ST, AP, SBr, FR, SBe, YA and TL interpreted the data.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The COBLAnCE project was funded by the French Ministry of Research (<italic toggle="yes">Programme Investissements d&#8217;Avenir Cohortes</italic>), the Institute of Research in Public Health - National Institute of Health and Medical Research, and the National League against Cancer. Sponsors were not involved in the COBLAnCE study design, the collection, analysis and interpretation of data. The current study was supported by Bristol Myers Squibb (Rueil-Malmaison, France) who provided funding for the preparation of this publication.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Anonymized data and biological samples collected during the study can be obtained for conducting scientific projects. Requests will be evaluated by the Scientific Committee of the COBLAnCE cohort.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par29">The study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements. The COBLAnCE study was approved by the relevant French ethics committee (<italic toggle="yes">Comit&#233; de Protection des Personnes Ile de France VII</italic>; approval n&#176; CO-12-001), the French data protection authority (Commission Nationale de l&#8217;Informatique et des Libert&#233;s; approval n&#176; DR-2012-441) and the French biological tissue collection authority (approval n&#176; DR-2012-1486). Each patient enrolled provided written informed consent. The current study did not require additional approval.</p></notes><notes id="FPar1"><title>Consent for publication</title><p id="Par30">Not applicable.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par31">Julia Bonastre reports consulting fees for scientific advisory board from Bristol-Myers Squibb (BMS), Merck Sharp &amp; Dohme (MSD), Janssen and Roche. Yves Allory reports fees to Institut Curie from Bristol Myers Squibb and Merck Sharp &amp; Dome. Thierry Lebret reports personal fees from Bristol Myers Squibb and Ferring. Simone Benhamou reports personal fees from AstraZeneca. Florian Colrat, Siguroli Teitsson, Alexis Prudent and S&#233;bastien Branchoux are employees of Bristol Myers Squibb. Ald&#233;ric Fraslin, Maryam Karimi, Karine Groussard and Fran&#231;ois Radvanyi declare no conflicts of interest.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>ASO</term><def><p id="Par32">Active surveillance only</p></def></def-item><def-item><term>BC</term><def><p id="Par33">Bladder cancer</p></def></def-item><def-item><term>BMI</term><def><p id="Par34">Body mass index</p></def></def-item><def-item><term>CI</term><def><p id="Par35">Confidence intervals</p></def></def-item><def-item><term>DFS</term><def><p id="Par36">Disease-free survival</p></def></def-item><def-item><term>EAU</term><def><p id="Par37">European Association of Urology</p></def></def-item><def-item><term>MIBC</term><def><p id="Par38">Muscle-invasive bladder cancer</p></def></def-item><def-item><term>MIBCHR</term><def><p id="Par39">Muscle-invasive bladder cancer at high risk of recurrence</p></def></def-item><def-item><term>OS</term><def><p id="Par40">Overall survival</p></def></def-item><def-item><term>PMSI</term><def><p id="Par41">Programme de M&#233;dicalisation des Syst&#232;mes d&#8217;Information (French national hospital database)</p></def></def-item><def-item><term>RC</term><def><p id="Par42">Radical cystectomy</p></def></def-item><def-item><term>SD</term><def><p id="Par43">Standard deviations</p></def></def-item><def-item><term>TNM</term><def><p id="Par44">Tumour Node Metastasis System</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Colombet</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Dyba</surname><given-names>T</given-names></name><name name-style="western"><surname>Randi</surname><given-names>G</given-names></name><name name-style="western"><surname>Bettio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018</article-title><source>Eur J Cancer</source><year>2018</year><volume>103</volume><fpage>356</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2018.07.005</pub-id><pub-id pub-id-type="pmid">30100160</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356&#8211;87. 10.1016/j.ejca.2018.07.005.<pub-id pub-id-type="pmid">30100160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2018.07.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder Cancer. Med Sci (Basel). 2020;8(1). 10.3390/medsci8010015.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/medsci8010015</pub-id><pub-id pub-id-type="pmcid">PMC7151633</pub-id><pub-id pub-id-type="pmid">32183076</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209&#8211;49. 10.3322/caac.21660.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenis</surname><given-names>AT</given-names></name><name name-style="western"><surname>Lec</surname><given-names>PM</given-names></name><name name-style="western"><surname>Chamie</surname><given-names>K</given-names></name><name name-style="western"><surname>Mshs</surname><given-names>MD</given-names></name></person-group><article-title>Bladder cancer: A review</article-title><source>JAMA</source><year>2020</year><volume>324</volume><issue>19</issue><fpage>1980</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.17598</pub-id><pub-id pub-id-type="pmid">33201207</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: A review. JAMA. 2020;324(19):1980&#8211;91. 10.1001/jama.2020.17598.<pub-id pub-id-type="pmid">33201207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.17598</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Brierley</surname><given-names>JG</given-names></name><name name-style="western"><surname>Wittekind</surname><given-names>MK</given-names></name></person-group><source>TNM classification of malignant tumours, eighth edition</source><year>2017</year><publisher-loc>Chichester, West Sussex, UK; Hoboken, NJ</publisher-loc><publisher-name>John Wiley &amp; Sons, Inc</publisher-name></element-citation><mixed-citation id="mc-CR5" publication-type="book">Brierley JG, Wittekind MK. C.: TNM classification of malignant tumours, eighth edition. Chichester, West Sussex, UK; Hoboken, NJ: John Wiley &amp; Sons, Inc; 2017.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witjes</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bruins</surname><given-names>HM</given-names></name><name name-style="western"><surname>Carri&#243;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Cathomas</surname><given-names>R</given-names></name><name name-style="western"><surname>Comp&#233;rat</surname><given-names>E</given-names></name><name name-style="western"><surname>Efstathiou</surname><given-names>JA</given-names></name><etal/></person-group><article-title>European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines</article-title><source>Eur Urol</source><year>2024</year><volume>85</volume><issue>1</issue><fpage>17</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2023.08.016</pub-id><pub-id pub-id-type="pmid">37858453</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Witjes JA, Bruins HM, Carri&#243;n A, Cathomas R, Comp&#233;rat E, Efstathiou JA, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17&#8211;31. 10.1016/j.eururo.2023.08.016.<pub-id pub-id-type="pmid">37858453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2023.08.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witjes</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bruins</surname><given-names>HM</given-names></name><name name-style="western"><surname>Cathomas</surname><given-names>R</given-names></name><name name-style="western"><surname>Comperat</surname><given-names>EM</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>NC</given-names></name><name name-style="western"><surname>Gakis</surname><given-names>G</given-names></name><etal/></person-group><article-title>European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines</article-title><source>Eur Urol</source><year>2021</year><volume>79</volume><issue>1</issue><fpage>82</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2020.03.055</pub-id><pub-id pub-id-type="pmid">32360052</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82&#8211;104. 10.1016/j.eururo.2020.03.055.<pub-id pub-id-type="pmid">32360052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2020.03.055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuzillet</surname><given-names>Y</given-names></name><name name-style="western"><surname>Audenet</surname><given-names>F</given-names></name><name name-style="western"><surname>Loriot</surname><given-names>Y</given-names></name><name name-style="western"><surname>Allory</surname><given-names>Y</given-names></name><name name-style="western"><surname>Masson-Lecomte</surname><given-names>A</given-names></name><name name-style="western"><surname>Leon</surname><given-names>P</given-names></name><etal/></person-group><article-title>French AFU Cancer committee Guidelines - Update 2022&#8211;2024: Muscle-Invasive bladder Cancer (MIBC)</article-title><source>Prog Urol</source><year>2022</year><volume>32</volume><issue>15</issue><fpage>1141</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.purol.2022.07.145</pub-id><pub-id pub-id-type="pmid">36400480</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Neuzillet Y, Audenet F, Loriot Y, Allory Y, Masson-Lecomte A, Leon P, et al. French AFU Cancer committee Guidelines - Update 2022&#8211;2024: Muscle-Invasive bladder Cancer (MIBC). Prog Urol. 2022;32(15):1141&#8211;63. 10.1016/j.purol.2022.07.145.<pub-id pub-id-type="pmid">36400480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.purol.2022.07.145</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benhamou</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonastre</surname><given-names>J</given-names></name><name name-style="western"><surname>Groussard</surname><given-names>K</given-names></name><name name-style="western"><surname>Radvanyi</surname><given-names>F</given-names></name><name name-style="western"><surname>Allory</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lebret</surname><given-names>T</given-names></name></person-group><article-title>A prospective multicenter study on bladder cancer: the coblance cohort</article-title><source>BMC Cancer</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>837</fpage><pub-id pub-id-type="doi">10.1186/s12885-016-2877-x</pub-id><pub-id pub-id-type="pmid">27809812</pub-id><pub-id pub-id-type="pmcid">PMC5094141</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Benhamou S, Bonastre J, Groussard K, Radvanyi F, Allory Y, Lebret T. A prospective multicenter study on bladder cancer: the coblance cohort. BMC Cancer. 2016;16(1):837. 10.1186/s12885-016-2877-x.<pub-id pub-id-type="pmid">27809812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-016-2877-x</pub-id><pub-id pub-id-type="pmcid">PMC5094141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebret</surname><given-names>T</given-names></name><name name-style="western"><surname>Bonastre</surname><given-names>J</given-names></name><name name-style="western"><surname>Fraslin</surname><given-names>A</given-names></name><name name-style="western"><surname>Neuzillet</surname><given-names>Y</given-names></name><name name-style="western"><surname>Droupy</surname><given-names>S</given-names></name><name name-style="western"><surname>Rebillard</surname><given-names>X</given-names></name><etal/></person-group><article-title>Cohort profile: coblance: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><issue>12</issue><fpage>e075942</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2023-075942</pub-id><pub-id pub-id-type="pmid">38128940</pub-id><pub-id pub-id-type="pmcid">PMC10749008</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Lebret T, Bonastre J, Fraslin A, Neuzillet Y, Droupy S, Rebillard X, et al. Cohort profile: coblance: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. BMJ Open. 2023;13(12):e075942. 10.1136/bmjopen-2023-075942.<pub-id pub-id-type="pmid">38128940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2023-075942</pub-id><pub-id pub-id-type="pmcid">PMC10749008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leow</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Martin-Doyle</surname><given-names>W</given-names></name><name name-style="western"><surname>Rajagopal</surname><given-names>PS</given-names></name><name name-style="western"><surname>Patel</surname><given-names>CG</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EM</given-names></name><name name-style="western"><surname>Rothman</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials</article-title><source>Eur Urol</source><year>2014</year><volume>66</volume><issue>1</issue><fpage>42</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.08.033</pub-id><pub-id pub-id-type="pmid">24018020</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42&#8211;54. 10.1016/j.eururo.2013.08.033.<pub-id pub-id-type="pmid">24018020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2013.08.033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sternberg</surname><given-names>CN</given-names></name><name name-style="western"><surname>Bellmunt</surname><given-names>J</given-names></name><name name-style="western"><surname>Sonpavde</surname><given-names>G</given-names></name><name name-style="western"><surname>Siefker-Radtke</surname><given-names>AO</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>WM</given-names></name><name name-style="western"><surname>Bajorin</surname><given-names>DF</given-names></name><etal/></person-group><article-title>ICUD-EAU international consultation on bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings</article-title><source>Eur Urol</source><year>2013</year><volume>63</volume><issue>1</issue><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.08.010</pub-id><pub-id pub-id-type="pmid">22917984</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, et al. ICUD-EAU international consultation on bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63(1):58&#8211;66. 10.1016/j.eururo.2012.08.010.<pub-id pub-id-type="pmid">22917984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2012.08.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sternberg</surname><given-names>CN</given-names></name><name name-style="western"><surname>Skoneczna</surname><given-names>I</given-names></name><name name-style="western"><surname>Kerst</surname><given-names>JM</given-names></name><name name-style="western"><surname>Albers</surname><given-names>P</given-names></name><name name-style="western"><surname>Fossa</surname><given-names>SD</given-names></name><name name-style="western"><surname>Agerbaek</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N + M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>76</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)71160-X</pub-id><pub-id pub-id-type="pmid">25498218</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N + M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76&#8211;86. 10.1016/S1470-2045(14)71160-X.<pub-id pub-id-type="pmid">25498218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(14)71160-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>S</given-names></name><name name-style="western"><surname>D&#8217;Andrea</surname><given-names>D</given-names></name><name name-style="western"><surname>Vetterlein</surname><given-names>MW</given-names></name><name name-style="western"><surname>Cole</surname><given-names>AP</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>SA</given-names></name><name name-style="western"><surname>Krimphove</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: does histologic subtype matter?</article-title><source>Cancer</source><year>2019</year><volume>125</volume><issue>9</issue><fpage>1449</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1002/cncr.31952</pub-id><pub-id pub-id-type="pmid">30620387</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Berg S, D&#8217;Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: does histologic subtype matter? Cancer. 2019;125(9):1449&#8211;58. 10.1002/cncr.31952.<pub-id pub-id-type="pmid">30620387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.31952</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galsky</surname><given-names>MD</given-names></name><name name-style="western"><surname>Stensland</surname><given-names>KD</given-names></name><name name-style="western"><surname>Moshier</surname><given-names>E</given-names></name><name name-style="western"><surname>Sfakianos</surname><given-names>JP</given-names></name><name name-style="western"><surname>McBride</surname><given-names>RB</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Effectiveness of adjuvant chemotherapy for locally advanced bladder Cancer</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><issue>8</issue><fpage>825</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.1076</pub-id><pub-id pub-id-type="pmid">26786930</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder Cancer. J Clin Oncol. 2016;34(8):825&#8211;32. 10.1200/JCO.2015.64.1076.<pub-id pub-id-type="pmid">26786930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2015.64.1076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roupret</surname><given-names>M</given-names></name><name name-style="western"><surname>Brouquet</surname><given-names>A</given-names></name><name name-style="western"><surname>Colrat</surname><given-names>F</given-names></name><name name-style="western"><surname>Diez-Andreu</surname><given-names>P</given-names></name><name name-style="western"><surname>Prudent</surname><given-names>A</given-names></name><name name-style="western"><surname>Chartier</surname><given-names>M</given-names></name><etal/></person-group><article-title>Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study</article-title><source>World J Urol</source><year>2023</year><volume>41</volume><issue>4</issue><fpage>1069</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s00345-023-04335-w</pub-id><pub-id pub-id-type="pmid">36929410</pub-id><pub-id pub-id-type="pmcid">PMC10018592</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Roupret M, Brouquet A, Colrat F, Diez-Andreu P, Prudent A, Chartier M, et al. Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study. World J Urol. 2023;41(4):1069&#8211;75. 10.1007/s00345-023-04335-w.<pub-id pub-id-type="pmid">36929410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-023-04335-w</pub-id><pub-id pub-id-type="pmcid">PMC10018592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Wen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Oncological outcome of primary and secondary Muscle-Invasive bladder cancer: A systematic review and Meta-analysis</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>7543</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26002-6</pub-id><pub-id pub-id-type="pmid">29765120</pub-id><pub-id pub-id-type="pmcid">PMC5954122</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ge P, Wang L, Lu M, Mao L, Li W, Wen R, et al. Oncological outcome of primary and secondary Muscle-Invasive bladder cancer: A systematic review and Meta-analysis. Sci Rep. 2018;8(1):7543. 10.1038/s41598-018-26002-6.<pub-id pub-id-type="pmid">29765120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-26002-6</pub-id><pub-id pub-id-type="pmcid">PMC5954122</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajorin</surname><given-names>DF</given-names></name><name name-style="western"><surname>Witjes</surname><given-names>JA</given-names></name><name name-style="western"><surname>Gschwend</surname><given-names>JE</given-names></name><name name-style="western"><surname>Schenker</surname><given-names>M</given-names></name><name name-style="western"><surname>Valderrama</surname><given-names>BP</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Adjuvant nivolumab versus placebo in Muscle-Invasive urothelial carcinoma</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>22</issue><fpage>2102</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034442</pub-id><pub-id pub-id-type="pmid">34077643</pub-id><pub-id pub-id-type="pmcid">PMC8215888</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in Muscle-Invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102&#8211;14. 10.1056/NEJMoa2034442.<pub-id pub-id-type="pmid">34077643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034442</pub-id><pub-id pub-id-type="pmcid">PMC8215888</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powles</surname><given-names>T</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Voog</surname><given-names>E</given-names></name><name name-style="western"><surname>Caserta</surname><given-names>C</given-names></name><name name-style="western"><surname>Valderrama</surname><given-names>BP</given-names></name><name name-style="western"><surname>Gurney</surname><given-names>H</given-names></name><etal/></person-group><article-title>Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>13</issue><fpage>1218</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002788</pub-id><pub-id pub-id-type="pmid">32945632</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218&#8211;30. 10.1056/NEJMoa2002788.<pub-id pub-id-type="pmid">32945632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2002788</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>